Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Bruyn1,2*, V. Ballet3, S. Verstockt4, B. Verstockt1,3, G. Van Assche1,3, M. Ferrante1,3, K. Machiels1, S. Vermeire1,3

Created: Thursday, 21 February 2019, 9:14 AM
OP004: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Stojmirovic*, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman

Created: Friday, 22 February 2019, 9:49 AM
OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Le Bourhis L.1, Corraliza A.2, Auzolle C.1, Ricart E.2, Hawkey C.3, Lindsay J.O.4, Clark M.3, Rogler G.5, Satsangui J.6, Haller D.7, Panes J.2, Salas A.2, Allez M.*1

Created: Wednesday, 20 February 2019, 10:36 AM
OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Schmitt1*, U. Billmeier1, J. Ulmschneider1, C. Admyre2, T. Knittel2, A. Zargari2, M.F. Neurath1, R. Atreya1

Created: Thursday, 21 February 2019, 9:14 AM
OP005: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Billiet*1, I. Cleynen1, M. Ferrante2, G. Van Assche2, A. Gils3, S. Vermeire2

Created: Friday, 22 February 2019, 9:49 AM
OP005: Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Danese1*, M. Neurath2, A. Kopon3, S. Zakko4, T. Simmons5, R. Fogel6, J. Maccarone7, X. Zhan7, K. Usiskin7, D. Chitkara7

Created: Thursday, 21 February 2019, 9:14 AM
OP005: The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Guidi L.1, Fiorino G.*2, Variola A.3, Manetti N.4, Fries W.5, Rizzuto G.6, Bossa F.7, Cappello M.8, Biancone L.9, D'Incà R.10, Cantoro L.11, Castiglione F.12, Principi M.13, Annunziata M.L.14, Di Girolamo M.15, Terpin M.M.16, Cortelezzi C.C.17, Costa F.18, Amato A.19, Di Sabatino A.20, Saibeni S.21, Meucci G.22, Petruzzellis C.23, Tari R.24, Gugliemi F.W.25, Armuzzi A.26, Danese S.2, Geccherle A.3, Rogai F.4, Ventra A.5, Orlando A.6, Andriulli A.7, Scrivo B.8, Troncone E.9, Caccaro R.10, Kohn A.11, Nardone O.12, Annese V.27

Created: Wednesday, 20 February 2019, 10:36 AM
OP006: Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Wildenberg*1, P. Koelink2, K. Diederen2, A. te Velde2, V. Nuij3, M. Peppelenbosch3, M. Nobis4, O. Sansom4, C.J. van der Woude3, G. D’Haens1, G. van den Brink1

Created: Friday, 22 February 2019, 9:49 AM
OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pouillon L.*1, Ferrante M.1, Van Assche G.1, Rutgeerts P.1, Noman M.1, Vande Casteele N.2, Gils A.3, Vermeire S.1

Created: Wednesday, 20 February 2019, 10:36 AM
OP006: Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Strik1*, M. Löwenberg1, C. Ponsioen1, K. Gecse2, C. Buskens3, W. Bemelman3, G. D’Haens1

Created: Thursday, 21 February 2019, 9:14 AM
OP007: α4β7 Integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Schleier1, M. Wiendl1, M.-T. Binder1, R. Atreya1, A. Watson2, C. Neufert1, I. Atreya1, M.F. Neurath1, S. Zundler1*

Created: Thursday, 21 February 2019, 9:14 AM
OP007: A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lawrance I.C.*1,2, Baird A.1, Lightowler D.2, Radford-Smith G.3, Andrews J.M.4, Connor S.5

Created: Wednesday, 20 February 2019, 10:36 AM
OP007: Comprehensive epigenome-wide DNA methylation profiling in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Ventham*1, N. Kennedy1, A. Adams1, R. Kalla1, S. Heath2, K. O’Leary1, H. Drummond1, D. Wilson3, T. IBD-BIOM Consortium1, T. IBD-CHARACTER Consortium1, I. Gut2, E. R. Nimmo1, J. Satsangi1

Created: Friday, 22 February 2019, 9:49 AM
OP008: An innovative treatment for refractory perianal fistulas in Crohn's disease: local micro reinjection of autologous fat and adipose derived stromal vascular fraction
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Serrero M.*1, Philandrianos C.2, Visee C.3, Veran J.2, Orsoni P.3, Sabatier F.2, Grimaud J.-C.1

Created: Wednesday, 20 February 2019, 10:36 AM
OP008: Detection of mucosal healing with a serum marker panel in adalimumab-treated patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Bruyn1,2*, R. Ringold3, E. Martens2, M. Ferrante1,4, G. Van Assche1,4, G. Opdenakker2, A. Dukler3, S. Vermeire1,4

Created: Thursday, 21 February 2019, 9:14 AM
OP008: Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Alberts*1, E. M. de Vries2, G. Alexander3, D. Alvaro4, A. Bergquist5, U. Beuers2, E. Björnsson6, K. M. Boberg7, C. L. Bowlus8, R. W. Chapman9, O. Chazouillères10, A. Cheung11, G. Dalekos12, B. Eksteen13, D. Ellinghaus14, M. Färkkilä15, E. A. Festen1, A. Floreani16, T. Folseraas7, E. Goode17, D. N. Gotthardt18, G. M. Hirschfield19, B. van Hoek20, K. Holm7, S. Hohenester21, J. R. Hov7, F. Imhann1, P. Invernizzi22, X. Jiang7, J. Eaton23, B. D. Juran24, K. N. Lazaridis24, V. Leppa25, J. Z. Liu26, J. Löfberg27, M. P. Manns28, H.-U. Marschall29, M. Marzioni30, A. L. Mason31, E. Melum7, P. Milkiewicz32, T. Müller33, A. Pares34, C. Rupp35, S. M. Rushbrook36, C. Rust37, F. Sampaziotis38, R. N. Sandford39, C. Schramm40, S. Schreiber14, E. Schrumpf7, M. Silverberg41, B. Srivastava39, M. Sterneck42, A. Teufel43, L. Tittmann44, L. Vallier38, A. V. Vila1, B. de Vries1, T. J. Weismüller28, C. Wijmenga45, K. Zachou46, A. Franke14, C. A. Anderson47, T. H. Karlsen7, C. Y. Ponsioen2, R. K. Weersma1

Created: Friday, 22 February 2019, 9:49 AM
OP009: A combination of clinical, serological, and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Sarter1,2*, G. Savoye3, D. Turck2,4, F. Vasseur5, G. Marot6,7, B. Pariente2,8, S. Singh9, J.F. Colombel10, C. Gower-Rousseau1,2, M. Fumery11

Created: Thursday, 21 February 2019, 9:14 AM
OP009: Gene-microbiome interactions underlying the onset and the clinical phenotypes of inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. Imhann*1, A. Vich Vila1, M. J. Bonder2, D. Gevers3, J. Fu2, M. C. Visschedijk1, L.M. Spekhorst1, L. Franke2, H. van Dullemen1, R. W. F. Ter Steege1, C. Huttenhower4, G. Dijkstra1, R. J. Xavier3, C. Wijmenga2, E. A. M. Festen1, A. Zhernakova2, R. K. Weersma1

Created: Friday, 22 February 2019, 9:49 AM
OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panes J.*1, García-Olmo D.2, Van Assche G.3, Colombel J.-F.4, Reinisch W.5, Baumgart D.C.6, Nachury M.7, Ferrante M.3, Kazemi-Shirazi L.5, Grimaud J.C.8, de la Portilla F.9, Goldin E.10, Richard M.P.11, Diez M.C.11, Danese S.12

Created: Wednesday, 20 February 2019, 10:36 AM
OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.F. Colombel1, J. Panés2, G. D’Haens3, S. Schreiber4, R. Panaccione5, L. Peyrin-Biroulet6, E.V. Loftus Jr7, S. Danese8, E. Louis9, A. Armuzzi10, M. Ferrante11, H. Vogelsang12, J. Lefebvre13, T. Doan14, W. Xie15, B. Huang15, J. Petersson16, J. Kalabic17, A. Robinson18, W.J. Sandborn19

Created: Thursday, 30 January 2020, 10:12 AM